Publications by authors named "M Beiner"
Introduction: The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a validated and highly utilized measure for evaluating patients with Friedreich Ataxia. While construct validity of FARS-ADL has been shown for spinocerebellar ataxia (SCA), content validity has not been established.
Methods: Individuals with SCA1 or SCA3 (n = 7) and healthcare professionals (HCPs) with SCA expertise (n = 8) participated in qualitative interviews evaluating the relevance, clarity, and clinical meaningfulness of FARS-ADL for assessment of individuals with SCA.
Introduction: The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a valid, highly utilized measure for assessing ADL impacts in patients with Friedreich ataxia. We provide evidence of the psychometric validity of the FARS-ADL in two cohorts of patients with spinocerebellar ataxia (SCA).
Methods: Using data from a cohort of real-world subjects with SCA (recruited at Massachusetts General Hospital [MGH]; n = 33) and a phase 3 trial of troriluzole in adults with SCA (NCT03701399 [Study 206]; n = 217), comprising a subset of patients with the SCA3 genotype (n = 89), the psychometric measurement properties and minimal change thresholds of the FARS-ADL were examined.
Article Synopsis
- Active fillers like carbon black and silica enhance the mechanical and viscoelastic properties of rubber through various interactions, affecting the compound's behavior.
- The study examines the effects of different silica loadings on three types of solution styrene-butadiene rubbers (SSBR) and one butadiene rubber (BR), finding that higher filler loading increases viscosity and hardness but can also worsen properties in BR due to weak polymer-filler interactions.
- An optimum filler loading was identified, where mechanical properties improved up to a point before declining, influenced by the type of rubber, amount of filler, and temperature.
Article Synopsis
- The study compared the combination of lenvatinib and pembrolizumab (len + pembro) with traditional chemotherapy for advanced or recurrent endometrial cancer (aEC) in patients who had not previously been treated.
- Results showed that while len + pembro did not statistically outperform chemotherapy in terms of progression-free survival (PFS) or overall survival (OS), it offered similar outcomes, indicating noninferiority.
- The trial involved 842 patients and found median PFS and OS were comparable between the two treatment groups, suggesting len + pembro could be an effective alternative to chemotherapy for this cancer type.
Novel fluorinated, pyrrolidinium-based dicationic ionic liquids (FDILs) as high-performance electrolytes in energy storage devices have been prepared, displaying unprecedented electrochemical stabilities (up to 7 V); thermal stability (up to 370 °C) and ion transport (up to 1.45 mS cm). FDILs were designed with a fluorinated ether linker and paired with TFSI/FSI counterions.
View Article and Find Full Text PDF